{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T05:04:32Z","timestamp":1649048672482},"reference-count":9,"publisher":"Carden Jennings Publishing Co.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Laboratory Hematology"],"published-print":{"date-parts":[[2012,12,1]]},"DOI":"10.1532\/lh96.12009","type":"journal-article","created":{"date-parts":[[2012,12,20]],"date-time":"2012-12-20T06:44:11Z","timestamp":1355985851000},"page":"20-21","source":"Crossref","is-referenced-by-count":0,"title":["The Incidence of Co-Existing &lt;i&gt;BCR-ABL1&lt;\/i&gt; and &lt;i&gt;JAK2&lt;\/i&gt; V617F Rearrangements: Implications for Molecular Diagnostics"],"prefix":"10.1532","volume":"18","author":[{"given":"Sarah L.","family":"McCarron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Haslam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireille","family":"Crampe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen E.","family":"Langabeer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"412","published-online":{"date-parts":[[2012,12,19]]},"reference":[{"key":"1","first-page":"461","article-title":"Uses and abuses of <i>JAK2<\/i> and MPL mutation tests in myeloproliferative neoplasms. A paper from the 2010 William Beaumont hospital symposium on molecular pathology","volume":"13","author":"A. Tefferi","year":"2011","journal-title":"J Mol Diagn"},{"key":"2","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1136\/jclinpath-2012-201008","article-title":"Referral centre variation in requesting <i>JAK2<\/i> V617F mutation analysis for the investigation of a myeloproliferative neoplasm","volume":"65","author":"S. Langabeer","year":"2012","journal-title":"J Clin Path"},{"key":"3","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/PDM.0b013e318246975e","article-title":"Concomitant <i>BCR-ABL1<\/i> translocation and <i>JAK2<\/i> V617F mutation in three patients with myeloproliferative neoplasms","volume":"21","author":"J. Hummel","year":"2012","journal-title":"Diagn Mol Pathol"},{"key":"4","doi-asserted-by":"crossref","DOI":"10.3816\/CLM.2009.n.080","article-title":"Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: <i>JAK2<\/i> V617F as a potential risk factor for BCR-ABL translocation","volume":"9","author":"S. Pingali","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"5","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1182\/blood-2011-07-365007","article-title":"Concomitant occurrence of BCR-ABL and <i>JAK2<\/i> V617F mutation","volume":"118","author":"L. Pieri","year":"2011","journal-title":"Blood"},{"key":"6","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2005-05-2087","article-title":"The V617F <i>JAK2<\/i> mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders","volume":"106","author":"L. Scott","year":"2005","journal-title":"Blood"},{"key":"7","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood-2005-05-1800","article-title":"<i>JAK2<\/i> mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-nagative CML, and megakaryocytic leukemia","volume":"106","author":"J. Jelinek","year":"2005","journal-title":"Blood"},{"key":"8","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase <i>JAK2<\/i> in human myeloproliferative disorders","volume":"365","author":"E. Baxter","year":"2005","journal-title":"Lancet"},{"key":"9","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1038\/sj.leu.2401592","article-title":"Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 concerted action: investigation of minimal residual disease in acute leukemia","volume":"13","author":"J. van Dongen","year":"1999","journal-title":"Leukemia"}],"container-title":["Laboratory Hematology"],"original-title":[],"deposited":{"date-parts":[[2017,6,21]],"date-time":"2017-06-21T04:31:35Z","timestamp":1498019495000},"score":1,"resource":{"primary":{"URL":"http:\/\/cardenjennings.metapress.com\/openurl.asp?genre=article&id=doi:10.1532\/LH96.12009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,1]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,12,1]]}},"alternative-id":["6165R1718X65P024"],"URL":"https:\/\/doi.org\/10.1532\/lh96.12009","relation":{},"ISSN":["1080-2924"],"issn-type":[{"value":"1080-2924","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12,1]]}}}